Navigation Links
Gallus BioPharmaceuticals Enters Clinical Supply Agreement with Genzyme for Niemann-Pick Type B Disease
Date:7/31/2013

St. Louis, Missouri (PRWEB) July 31, 2013

Gallus Biopharmaceuticals, LLC (Gallus) has signed a development and manufacturing supply agreement with Genzyme, a Sanofi Company the pioneer in the development and delivery of transformative therapies for patients with rare and special unmet medical needs for over 30 years. As part of the multi-year agreement Gallus will provide process and method development, scale-up, clinical supply and preparation for commercial manufacturing for an infused protein-based therapy targeting the rare disease, Niemann-Pick type B. "Gallus is delighted to partner with Genzyme in bringing this therapy to patients in need," said Mark Bamforth, Gallus’ CEO and President. "We are confident that our deep process development expertise and over ten years of commercial, perfusion-based biomanufacturing for global markets using proprietary, flexible stainless steel bioreactors will result in successful delivery of this therapeutic molecule to advance Genzyme’s clinical program."

Niemann-Pick type B is caused by a deficiency of an enzyme called acid sphingomyelinase, which is required for the normal turnover of sphingomyelin, a major lipid of cell membranes. The enzyme deficiency causes sphingomyelin to accumulate in patients and leads to enlargement of the liver and spleen, lung disease, low blood cell counts and in some cases a shortened lifespan.

About Gallus BioPharmaceuticals

Gallus BioPharmaceuticals is a leading contract manufacturing company offering exceptional contract services to its clients. The firm, based in St. Louis, Missouri, was established in 2010 and acquired a world class commercial biopharmaceutical manufacturing facility from Johnson & Johnson’s Centocor division in 2011 and has grown its workforce by over 50% since then. In addition to process development and clinical supply services, Gallus currently produces two commercial products that are distributed globally. The St. Louis facility has been inspected and approved by every major regulatory body worldwide. For additional information on biopharmaceutical contract development and manufacturing services, visit http://www.gallusbiopharma.com or email info(at)gallusbiopharma(dot)com.

Genzyme® is the registered trademark of Genzyme Corporation. All rights reserved.

For more information:
Contact: Claire Ruzicka
Title: Sr. Marketing Manager
Gallus BioPharmaceuticals, LLC
4766 LaGuardia Drive
St. Louis, MO 63134-3117
USA
Telephone: +1 314-733-3814
Email: claire.ruzicka(at)gallusbiopharma(dot)com

Read the full story at http://www.prweb.com/releases/2013/7/prweb10981911.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
2. PolyTherics and Antitope Combine to Create Leading Provider of Solutions to Enable the Development of Better Biopharmaceuticals
3. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
4. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
5. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
6. Leica Biosystems and Synthon Biopharmaceuticals Partner to Develop a Companion Diagnostic Program for Targeted Cancer Therapies
7. Keryx Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference Presentation Scheduled for Monday, February 11th at 2:30 PM ET
8. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
9. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
10. Mangrove Partners Agrees to Support Amended Transaction Between Nabi Biopharmaceuticals and Biota Holdings
11. Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... ... February 04, 2016 , ... Shimadzu ... quad LC-MS, host live demos and poster sessions, and present on the analysis ... conference takes place March 6 to 10 at the Georgia World Congress Center ...
(Date:2/4/2016)... MONMOUTH JUNCTION, N.J. , Feb. 4, 2016 ... critical care immunotherapy leader commercializing its flagship CytoSorb® ... and cardiac surgery patients around the world, announced ... PhD, will present at the Source Capital Group,s ... overview and update on the company.  ...
(Date:2/4/2016)... ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), ... of targeted antiviral therapies, announced today that it will ... be held February 8-9, 2016, at the Waldorf Astoria ... & Healthcare Conference, taking place in New ... James Sapirstein , Chief Executive Officer of ContraVir, will ...
(Date:2/4/2016)... Oakland, California (PRWEB) , ... February 04, 2016 ... ... Artificial Intelligence (AI) and leading supplier of Semantic Graph Database technology has been ... Graph Database Products ” by Corporate America Magazine. , “At Corporate America, it’s ...
Breaking Biology Technology:
(Date:1/25/2016)... Pa. , Jan. 25, 2016   Unisys Corporation ... system at John F. Kennedy (JFK) International Airport, New ... Protection (CBP) identify imposters attempting to enter the ... not belong to them. pilot testing of the ... initially at three terminals at JFK during January 2016. --> ...
(Date:1/21/2016)... PUNE, India , January 21, 2016 /PRNewswire/ ... According to a new market research report "Emotion ... Learning, and Others), Software Tools (Facial Expression, Voice ... and Regions - Global forecast to 2020", published ... Market is expected to reach USD 22.65 Billion ...
(Date:1/18/2016)... , Jan. 18, 2016  Extenua Inc., a ... simplifies the use and access of ubiquitous on-premise ... partnership with American Cyber.  ... experience leading transformational C4ISR and Cyber initiatives in ... the latest proven technology solutions," said Steve ...
Breaking Biology News(10 mins):